Graves' Disease clinical trials at UCSF
1 research study open to eligible people
Graves' disease causes an overactive thyroid due to immune system attacks. UCSF conducts research testing IMVT-1402 for adults with Graves' Disease. This helps determine whether the treatment is effective and what its potential side effects are.
IMVT-1402 as Treatment for Adult Participants With Graves' Disease
open to eligible people ages 18-75
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
San Francisco, California and other locations
Last updated: